Core--Pathology/Genotyping

核心--病理学/基因分型

• 批准号: 7102939
• 负责人: SCOTT M LIPPMAN
• 金额: $ 42.26万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-04-01 至 2010-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7102939
• 关键词: biomedical facility; genetic screening; genotype; human genetic material tag; human tissue; neoplasm /cancer diagnosis; nucleic acid amplification techniques; nucleic acid quantitation /detection; pathology; prostate neoplasms; sample collection; tissue /cell preparation; tissue resource /registry

DESCRIPTION (provided by applicant): The Southwest Oncology Group-led Prostate Cancer Prevention Trial (PCPT) was the first large-scale chemoprevention trial for prostate cancer (PCa). This trial, which enrolled >18,800 men, tested the ability of the 5-alpha-reductase inhibitor finasteride to reduce the period-prevalence of biopsy-proven PCa over a period of 7 years. A byproduct of the PCPT was the establishment of large specimen banks of biopsy tissue, prostatectomy specimens, serum, plasma, and white blood cells obtained from the participants at the end of the study and at various interim time points during the study. The overall aim of this revised application for Core C is to establish a Pathology and Genotyping Core in support of the molecular "Biology of the PCPT" Program Project. This core will provide expertise and resources in the following areas: 1) Archival Repository Management and Distribution of the various specimen banks established from the PCPT; 2) Histopathology, including diagnostic interpretation, microtomy, microscopy, laser-capture microdissection (LCM), immunohistochemistry (IHC), and computer-assisted image analysis; and 3) Genotyping and hormone analysis, overseeing the isolation of DNA, genotyping of samples and hormone analysis to be carried out by specialized central facilities. This revised proposal addresses all of the comments from the review of the original proposal and adds new preliminary data regarding reliability and quantification of IHC, quantification of DNA extracted from serum, and extraction and amplification of DNA from paraffin-embedded tissue sections using LCM. Genotyping has also been streamlined to ensure sufficient DNA for the proposed studies and for future PCPT biology studies. Our intent is to provide the highest quality samples and pathological services to meet the needs of the research teams in the Program Project. It is our underlying hypothesis that the quality, reliability and applicability of translational research in PCa can only be guaranteed through the use of high-quality biological specimens that are handled, processed and interpreted in a uniform manner and that can be linked to clinical information and outcome.

描述（由申请人提供）：西南肿瘤学组领导的前列腺癌 预防试验（PCPT）是第一个针对前列腺癌（PCa）的大规模化学预防试验。这项试验招募了超过 18,800 名男性，测试了 5-α 还原酶抑制剂非那雄胺在 7 年时间内降低经活检证实的 PCa 患病率的能力。 PCPT 的一个副产品是建立了大型样本库，其中包括在研究结束时和研究期间的各个中间时间点从参与者获得的活检组织、前列腺切除标本、血清、血浆和白细胞。核心 C 修订版申请的总体目标是建立病理学和基因分型核心，以支持分子“PCPT 生物学”计划项目。该核心将提供以下领域的专业知识和资源： 1） PCPT 建立的各种样本库的档案存储库管理和分发； 2）组织病理学，包括诊断解释、切片、显微镜、激光捕获显微切割（LCM）、免疫组织化学（IHC）和计算机辅助图像分析； 3) 基因分型和激素分析，监督由专门的中心设施进行的 DNA 分离、样本基因分型和激素分析。该修订后的提案解决了原始提案审查中的所有意见，并添加了有关 IHC 的可靠性和定量、从血清中提取的 DNA 的定量以及使用 LCM 从石蜡包埋的组织切片中提取和扩增 DNA 的新的初步数据。基因分型也得到简化，以确保有足够的 DNA 用于拟议的研究和未来的 PCPT 生物学研究。我们的目的是提供最高质量的样本和病理服务，以满足项目研究团队的需求。我们的基本假设是质量、可靠性和 PCa 转化研究的适用性只能通过使用高质量的生物标本来保证，这些标本以统一的方式处理、处理和解释，并且可以与临床信息和结果联系起来。